Compare Domino's Pizza, Inc. (DPZ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs BIO-TECHNE Corp — how do they compare? Domino's Pizza, Inc. trades at $309.9 (market cap $10.31B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Domino's Pizza, Inc. and BIO-TECHNE Corp are close in size by market cap, and Domino's Pizza, Inc. pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| DPZ | TECH | |
|---|---|---|
Market Cap | $10.31B | $11.12B |
Sector | Consumer Cyclical | Health |
52-Week High | $485.53 | $71.38 |
52-Week Low | $282.89 | $43.31 |
Enterprise Value | $15.21B | $11.20B |
Dividend Yield | 2.57% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
